-The Times of India The free trade agreement that European Union is pushing India to sign could put an end to India's status as the pharmacy of the developing providing affordable medicines, especially HIV drugs to countries like Brazil, Thailand, South Africa, Zimbabwe and several others. The negotiations with EU are on at a feverish pace this week in Brussels even before the parliamentary standing committee looking into the free trade...
More »SEARCH RESULT
Total Matching Records found : 520
Sickle cell disease killing tribals, dalits in MP -Manjari Mishra
-The Times of India MANDLA/JABALPUR: Tribals in Kundam, a settlement 40 km off Jabalpur, call it a black demon, one who strikes select families and ensures an early and agonizing death by sucking its victims white. For once, medical experts couldn't agree more with this home spun wisdom that aptly describes sickle cell - an incurable genetic disorder which damages vital organs like liver, kidney, heart and spleen. The disease manifest at...
More »Patients win over patents-Srividhya Ragavan
-The Hindu Justice Prabha Sridevan’s judgment permitting the production and sale of a generic version of a cancer drug is a victory for patients. It posits the public interest, especially in matters of health care, right at the heart of intellectual property rights in India Monday was a remarkable day for cancer patients in India. To them, the country said — “we care.” I am talking about the astounding decision by Justice...
More »Bayer plea dismissed, Natco allowed to sell patent cancer drug
-The Business Standard Chennai: The Intellectual Property Appellate Board (IPAB) today upheld a compulsory licence issued by the Controller of patents to Hyderabad-based Natco Pharma Ltd, a generic drug maker, to manufacture and sell a cancer drug of Bayer Corp in India. IPAB, however, made changes in the licence order by increasing the royalty payment to Bayer Corp for Nexavar, used to treat liver and kidney cancer, from six per cent to...
More »Natco Pharma wins cancer drug case-R Sivaraman
-The Hindu Bayer's plea dismissed by the Intellectual Property Appellate Board The Intellectual Property Appellate Board (IPAB) on Monday upheld the grant of compulsory licence (CL) to the Hyderabad-based Natco Pharma Limited, a generic drug maker, to produce and market Nexavar, a patented cancer drug of multinational pharma major Bayer Corporation. The order will pave the way for reduction in the prices of costly life saving drugs. Disposing an appeal filed by Bayer...
More »
